Home Info-Graphs Regeneron, McKesson, WABCO, Middleby: Scary Stock Tops To Avoid

Regeneron, McKesson, WABCO, Middleby: Scary Stock Tops To Avoid

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.


Regeneron, McKesson, WABCO, Middleby: Scary Stock Tops To Avoid by Eric Bush, CFA – Gavekal Capital Blog

Company: Regeneron Pharmaceuticals

Sector: Health Care

Sub-Industry: Biotechnology

Key Valuation Metrics:

  • Price to Cash Flow (P/CF): 30.2x
  • Price to Earnings (P/E): 63.2x
  • Price to Book Value (P/BV): 11x
  • Normalized P/CF (5-year trailing): 78.2x
  • Normalized P/E: 98.5x
  • Normalized P/B: 19.3x

Company: McKesson Corp

Sector: Health Care

Sub-Industry: Health Care Distributors

Key Valuation Metrics:

  • Price to Cash Flow (P/CF): 11.6x
  • Price to Earnings (P/E): 20.3x
  • Price to Book Value (P/BV): 3.8x
  • Normalized P/CF: 13.1x
  • Normalized P/E: 26.1x
  • Normalized P/B: 4.5x

McKesson Corp

Company: WABCO

Sector: Industrials

Sub-Industry: Construction Machinery & Heavy Trucks

Key Valuation Metrics:

  • Price to Cash Flow (P/CF): 13.5x
  • Price to Earnings (P/E): 19.4x
  • Price to Book Value (P/BV): 6.4x
  • Normalized P/CF: 20.4x
  • Normalized P/E: 23x
  • Normalized P/B: 4.5x

WABCO

Company: Middleby Corp

Sector: Industrials

Sub-Industry: Industrial Machinery

Key Valuation Metrics:

  • Price to Cash Flow (P/CF): 22.7x
  • Price to Earnings (P/E): 27.4x
  • Price to Book Value (P/BV): 5.3x
  • Normalized P/CF: 35.3x
  • Normalized P/E: 40.9x
  • Normalized P/B: 7.6x

Middleby Corp

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.